chrom,start_hg38,stop_hg38,start_hg19,stop_hg19,start_t2t,stop_t2t,notes_t2t,id,disease_id,gene_strand,reference_motif_reference_orientation,pathogenic_motif_reference_orientation,pathogenic_motif_gene_orientation,benign_motif_reference_orientation,benign_motif_gene_orientation,unknown_motif_reference_orientation,unknown_motif_gene_orientation,disease,gene,locus_structure,Inheritance,type,location_in_gene,normal,normal_min,normal_max,intermediate,intermediate_min,intermediate_max,pathogenic,pathogenic_min,pathogenic_max,ref_copies,repeatunitlen,age_onset,age_onset_min,age_onset_max,novel,Mechanism,Mechanism_detail,Mechanism_source,source,notes,details,width,OMIM,Incidence,Prevalence,STRipy_gene,gnomAD_gene,GeneReviews
chrX,148500605,148500753,147582125,147582273,146765191,146765342,(GCC)51.3,FRAXE_AFF2,FRAXE,+,CGG,GCC,,,,,,"Fragile X syndrome, FRAXE type",AFF2/FMR2,"""(GCC)*""",XR,5' UTR,5’ Region,4-39,4,39,,,,200-2000,200,2000,50.3,3,2-10,2,10,ref,"LOF, reduced gene expression",Loss of function via transcriptional silencing,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, OMIM, GeneReviews NBK535148",,,148,309548,,Unknown,AFF2,AFF2,NBK535148
chr2,100104799,100104824,100721261,100721286,100563686,100563738,(GCC)17.7,FRA2A_AFF3,FRA2A,-,GCC,CGG,,,,,,Intellectual disability associated with fragile site FRA2A,AFF3,,AD,5' UTR,,3-20,3,20,,,,300,300,300,8.7,3,,,,ref,"Decreased gene expression, methylation","""silencing of the FMR2 gene as a consequence of a CCG expansion located upstream of this gene""",malacard,"https://doi.org/10.1038/s41580-021-00382-6, PMC3998887","Path threshold may actually be higher than 300, assay was not sensitive enough",,25,,,,,,
chrX,67545317,67545419,66765159,66765261,65975148,65975250,(GCA)33.3,SBMA_AR,SBMA,+,CAG,GCA,,,,,,"Spinal and bulbar muscular atrophy, Kennedy Disease",AR,"""(GCA)*""",XR,Coding,Exon 1,9–34,9,34,36-37,36,37,38–68,38,68,34.0,3,20-49,20,49,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x",,,102,313200,,"1:300,000 males (SBMA); 1/40,000 (Kennedy Disease)",AR,AR,NBK1333
chrX,25013654,25013697,25031779,25031808,24597891,24597934,(GCC)14.7,EIEE1_ARX,EIEE1,-,NGC,NGC,,,,,,Early-infantile epileptic encephalopathy,ARX," ""(NGC)*""",XR,Coding,Exon 2,10-16,10,16,,,,17-27,17,27,14.7,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"GeneReviews NBK535148, OMIM",Exon 2 aa 110-115,,43,308350; 300419; 300215,"1-2/100,000","~<1/35,000",ARX_1,ARX_1,NBK535148
chrX,25013530,25013565,25031647,25031682,24597767,24597799,(GGCCGCGGCGGCCGC)2.2,PRTS_ARX,PRTS,-,NGC,NGC,,,,,,Partington syndrome,ARX,"""(NGC)*""",XR,Coding,Exon 2,12,12,12,,,,20,20,20,12.0,3,1-3,1,3,ref,Polyalanine,Polyalanine,(OMIM) (doi.org/10.1007/s11604-022-01343-5),"GeneReviews NBK535148, OMIM","Novel, Exon 2 aa 144-155",,35,309510,,Unknown,ARX_2,ARX_2,NBK535148
chr12,6936717,6936775,7045880,7045938,6947904,6947941,(CAG)12.7,DRPLA_ATN1,DRPLA,+,CAG,CAG,,,,,,Dentatorubral-Pallidoluysian Atrophy,ATN1,"""(CAG)*""",AD,Coding,Exon 5,3–35,3,35,,,,48-93,48,93,19.0,3,1-72,1,72,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x",,,58,125370,,"2-7/1,000,000",ATN1,ATN1,NBK1491
chr6,16327634,16327724,16327865,16327955,16200189,16200282,(TGC)31.1,SCA1_ATXN1,SCA1,-,CTG,CTG,,,,,,Spinocerebellar Ataxia Type 1,ATXN1,"""(TGC)*""",AD,Coding,Exon 8,6–35,6,35,36-38,36,38,39–91,39,91,30.3,3,20-40 typical,13,60,ref,Polyglutamine,Polyglutamine,(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK1184, s40478-021-01201-x",Interruptions: CAT,,90,164400,,"1-2/100,000",ATXN1,ATXN1,NBK1184
chr22,45795355,45795424,46191235,46191304,46280060,46280129,(ATTCT)15.0,SCA10_ATXN10,SCA10,+,ATTCT,ATTCT,,,,,,Spinocerebellar Ataxia Type 10,ATXN10,"""(ATTCT)*""",AD,Intronic,Intron 9/11,10–32,10,32,280-850,280,850,800-4500,800,4500,14.0,5,12-48,12,48,ref,Unknown,Transdominant mechanism theorized,(malacard),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x",Interruptions: ATCCT,,69,603516,,Unknown,ATXN10,ATXN10,
chr12,111598950,111599019,112036754,112036823,111575873,111575940,(GCT)22.3,SCA2_ATXN2,SCA2,-,CTG,GCT,,,,,,Spinocerebellar Ataxia Type 2,ATXN2,"""(GCT)*""",AD/AR,Coding,Exon 1,14–31,14,31,32-34,32,34,33–200,33,200,23.3,3,30-40 typical,25,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, GeneReviews NBK1275, s40478-021-01201-x","29–32 repeats: increased ALS risk, Interruptions: CAA, CGG, CGC. Parkinson disease, late-onset, susceptibility.",,69,183090,,"1-2/100,000 (population dependent)",ATXN2,ATXN2,NBK1275
chr14,92071012,92071053,92537356,92537397,86300520,86300603,(CTG)28.0,SCA3_ATXN3,SCA3_MJD,-,CTG,CTG,,,,,,Spinocerebellar Ataxia Type 3/Machado-Joseph Disease,ATXN3,"""(GCT)*""",AD,Coding,Second last exon,12–44,12,44,45-59,45,59,60-87,60,87,14.0,3,10-50 typical,10,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x","""14:92071009-92071042""",,41,109150,,"1–5/100,000",ATXN3,ATXN3,NBK1196
chr3,63912685,63912716,63898361,63898392,63956303,63956334,(GCA)10.7,SCA7_ATXN7,SCA7,+,CAG,GCA,,,,,,Spinocerebellar Ataxia Type 7,ATXN7,"""(GCA)*(GCC)+""",AD,Coding,"Exon 1, 2, or 3 (depending on isoform)",4–19,4,19,28-35,28,35,34–460,34,460,10.7,3,0-50,0,50,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x",,,31,164500,,"<1/300,000",ATXN7,ATXN7,NBK1256
chr13,70139383,70139429,70713515,70713561,69361244,69361271,(CTG)9.3,SCA8_ATXN8OS,SCA8,+,CTG,CTG,,,,,,Spinocerebellar Ataxia Type 8,ATXN8OS/ATXN8,"""(CTA)*(CTG)*""",AD,3' UTR,Exon 5 or 3’ UTR depending on transcript,15–50,15,50,50-70,50,70,71-1300,71,1300,15.3,3,20-50 typical,1,73,ref,"Polyglutamine/toxic gain-of-function; Unknown ","Polyglutamine/toxic gain-of-function; Unknown ",(OMIM) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x","Two genes span the CTG/CAG repeat and are expressed in opposite directions: ATXN8, which encodes a nearly pure polyglutamine expansion protein in the CAG direction, and ATXN8OS (603680), which, when transcribed, produces a noncoding CUG expansion RNA (Moseley et al., 2006). Roda et al. suggested that the ATXN8 or ATXN8OS gene should not be evaluated in isolation as a candidate gene for spinocerebellar degenerative disease",,46,608768,,"<1/100,000",ATXN8OS,ATXN8OS,NBK1268
chr16,66490397,66490466,66524300,66524369,72284667,72284761,(AATAA)19.4,SCA31_BEAN1,SCA31,+,AATAA,"TGGAA,TAGAA",,,,"AAAAA,AAAAC,AAATG,AGAAA,ATAAG,TAAAC,TAACA,TACAA,TCAAA,TGCAA",,Spinocerebellar Ataxia Type 31,BEAN1,"""(TGGAA)*TAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAATAAAA""",AD,Intronic,Intron 4/4,0-10,0,10,,,,>110,110,760,14.4,5,20-72,20,72,novel,Epigenetic,"Role in heterochromatin or chromosomal structure theorized ",(OMIM),"OMIM, Sato 2009, 19878914 (Pubmed), https://doi.org/10.1038/s41580-021-00382-6","Novel, STR-containing insertion, not present in reference genome: Reds disagree on normal/pathogenic sizes",,69,117210,,Unknown (more common in Japanese pop),BEAN1,BEAN1,NBK535148
chr9,27573484,27573546,27573482,27573544,27584063,27584155,(GCCCCG)15.8,FTDALS1_C9orf72,FTDALS1,-,GCCCCG,GGCCCC,,,,,,Frontotemporal dementia (FTD) and/or amyotrophic lateral sclerosis (ALS),C9orf72,"""(GGCCCC)*""",AD,Intronic,Intron 1 or 5' depending on transcript,3–25 (2-19 Reds),2,20,20-60,20,60,250-2000,250,2000,10.8,6,27-85,27,85,ref,RNA toxicity proposed,"""The HRE forms DNA and RNA G-quadruplexes with distinct structures and promotes RNA/DNA hybrids (R-loops). The structural polymorphism causes a repeat length-dependent accumulation of transcripts aborted in the HRE region.""",OMIM,"Hannan 2018, GeneReviews NBK535148, OMIM, s40478-021-01201-x",,,62,105500,,The expansion of a hexanucleotide repeat GGGGCC in C9orf72 is the most common known cause of ALS accounting for ~ 40% familial cases and ~ 7% sporadic cases in the European population,C9ORF72,C9ORF72,NBK268647
chr19,13207859,13207898,13318673,13318712,13333137,13333176,(CTG)13.3,SCA6_CACNA1A,SCA6,-,CTG,CTG,,,,,,Spinocerebellar Ataxia Type 6,CACNA1A,"""(CTG)*""",AD,Coding,Last Exon: 47 or 48,4–18,4,18,19,19,19,20–33,20,33,13.3,3,19-73,19,73,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148, s40478-021-01201-x",,,39,183086,,"<1/1,000,000",CACNA1A,CACNA1A,NBK1140
chr11,119206289,119206322,119076999,119077032,119226663,119226696,(CGG)11.3,JBS_CBL2,JBS,+,CGG,CCG,,,,,,Jacobsen syndrome (FRAX11B fragile site),CBL2,"""(CGG)*""",AD,5' UTR,,<79,11,79,,,,>100,100,100,11.3,3,,0,0,ref,,No information found,(OMIM),"https://doi.org/10.1038/s41580-021-00382-6, 7603564 (PubMed)",,,33,147791,,"1/100,000 births",CBL,,
chr19,18786034,18786049,18896844,18896859,18921630,18921645,,EDM1-PSACH_COMP,"EDM1, PSACH",-,GTC,GTC,,,,,,"Multiple epiphyseal dysplasia, Pseudoachondroplasia",COMP,,AD,Coding,,5,5,5,,,,4 or 6-7,6,7,5.0,3,13,13,13,ref,Protein LOF,"LOF, domain dependent",(https://pubmed.ncbi.nlm.nih.gov/29530484/),Pathogenic Short Tandem Repeats Gnomad v3.1.2,"Two diseases, same locus. Both expansions and contractions associated with disease",,15,132400; 177170,,"9-16/100,000 births",COMP,COMP,NBK1123; NBK1487
chr1,57367044,57367125,57832716,57832797,57245936,57245977,(AAAAT)8.6,SCA37_DAB1,SCA37,-,AAAAT,ATTTC,,,,AAAAA,,Spinocerebellar Ataxia Type 37,DAB1,"""(AAAAT)*(GAAAT)*(AAAAT)*""",AD,Intronic,Intron 1 (most isoforms),0-16,0,16,,,,31-75,31,75,16.6,5,18-64,18,64,novel,Protein toxic GOF,toxic gain-of-function mechanism,(OMIM),"Seixas et al 2017 AJHG, NBK541729, s40478-021-01201-x","Novel. Normal: [(ATTTT)7–400] Pathogenic: [(ATTTT)60–79(ATTTC)31–75(ATTTT)58–90], ATTTC within (ATTTT)7–400 repeat region",,81,615945,,"<1/1,000,000",DAB1,DAB1,NBK541729
chr12,50505002,50505022,50898785,50898805,50468096,50468116,,FRA12A_DIP2B,FRA12A,+,CGG,GGC,,,,,,"Intellectual developmental disorder, FRA12A type",DIP2B,"""(GGC)*""",AD,5' UTR,,6-23,6,23,~139-206,139,206,~273-306,273,306,7.0,3,,1,1,ref,"Increased gene expression, methylation","Increased gene expression, methylation","(OMIM, https://www.medrxiv.org/content/10.1101/2022.09.12.22279739v3.full-text)","OMIM, NBK535148, https://www.medrxiv.org/content/10.1101/2022.09.12.22279739v3.full-text",,,20,136630,,,DIP2B,DIP2B,NBK535148
chrX,31284557,31284605,31302674,31302722,30882695,30882743,(TTC)22.7,DMD_DMD,DMD,-,TTC,TTC,,,,,,Duchenne muscular dystrophy,DMD,,XR,Intronic,,<33,16,33,,,,>59,59,59,16.7,3,dependent on repeat number (birth to adulthood),0,3,ref,Protein LOF,Functional defect in dystrophin/dystroglycan,(https://doi.org/10.1007/s10038-006-0056-7),PMID: 27417533,,There is conflicting evidence for the association between this repeat expansion and Duchenne muscular dystrophy. The association was reported in a single family (PMID: 27417533). The population frequency of the proposed pathogenic allele is much higher than expected for a highly penetrant early-onset condition.,48,310200,,"1 in 3,500-5,000 live male births",DMD,DMD,NBK535148
chr19,45770204,45770266,46273462,46273524,48597739,48597756,,DM1_DMPK,DM1,-,CAG,CAG,,,,,,Myotonic Dystrophy Type 1,DMPK,"""(CAG)*""",AD,3' UTR,Last exon,5–34,5,34,35-49,35,49,50-1000,50,1000,20.7,3,"0-30, mild up to 70",0,70,ref,RNA GOF,RNA gain-of-function - RNA gelation leading to misregulation of alternative splicing,(doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK1165, s40478-021-01201-x",Interruptions: CCG,,62,160900,,"5-20/100,000",DMPK,DMPK,NBK1165
chrX,147912037,147912111,146993555,146993629,146176665,146176769,(GGC)35.0,FXS_FMR1,FXS/FXTAS/POF1,+,CGG,CGG,,,,,,"Fragile X syndrome (FXS), fragile X-associated tremor/ataxia syndrome (FXTAS), and fragile X-associated primary ovarian insufficiency FXPOI/POF1",FMR1,"""(CGG)*""",XD,5' UTR,Exon 2,5–44,5,44,45-200,45,200,200-2000,200,2000,20.6667,3,"FXS 2, FXTAS 60-65",2,65,ref,"LOF via decreased gene expression in FXS, GOF in FXTAS",Loss of function via transcriptional silencing in FXSRNA GOF in FXTAS,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, NBK1384","FXTAS/POI 55–200, FXS >200, late onset",,74,300624; 300623,,"16-25/100,000 males",FMR1,FMR1,NBK1384
chr3,138946020,138946062,138664862,138664904,141687014,141687051,(GCGGCTGCAGCCGCA)2.5,BPES_FOXL2,BPES,-,NGC,NGC,,,,,,"Blepharophimosis, epicanthus inversus, and ptosis",FOXL2,"""(NGC)*""",AD,Coding,Exon 1,<14,14,14,,,,>15,15,15,14.0,3,"0, can have infertility in childbearing age",0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),NBK535148,,,42,110100,,"1 in 50,000 births globally",FOXL2,FOXL2,NBK535148
chr9,69037287,69037289,71652203,71652205,81210844,81210846,(AAG)9.7,FRDA_FXN,FRDA,+,GAA,GAA,,,,,,Friedreich ataxia,FXN,"""(A)*(GAA)*",AR,Intronic,Intron 1,5–33,5,33,34-65,34,65,66 to 1700,66,1700,6.0,3,5-25,5,25,ref,"LOF, reduced gene expression",Loss of function via transcriptional silencing,(doi.org/10.1038/nrg1691) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK535148",Not annotated by TRF?,,2,229300,,"1/50,000 (US), 1/40,000 (global)",FXN,FXN,NBK1281
chr19,14496041,14496074,14606853,14606886,14622656,14622702,(CCG)15.7,OPDM2_GIPC1,OPDM2,-,CCG,CCG,,,,,,Oculopharyngodistal myopathy,GIPC1,"""(CCG)*""",AD,5' UTR,Exon 1,6-29,6,29,,,,70-138,70,138,14.7,3,10-29,10,29,ref,RNA toxicity,RNA mediated toxicity hypothesized; unknown,"(OMIM), (doi.org/10.1007/s11604-022-01343-5)","Pathogenic Short Tandem Repeats Gnomad v3.1.2, 32413282 (Pubmed)",,,33,618940,,Population dependent,GIPC1,GIPC1,NBK535148
chr2,190880873,190880920,191745599,191745646,191369983,191370024,(GCA)14.0,GDPAG_GLS,GDPAG,+,GCA,GCA,,,,,,Glutaminase deficiency,GLS,"""(GCA)*""",AR,5' UTR,Exon 1,5-26,5,26,,,,90 - 1500,90,1500,16.0,3,Early childhood,0,1,ref,"Decreased gene expression, methylation",Change in histone modification decreases transcription,(OMIM),"van Kuilenburg 2019 NEJM, 30970188 (Pubmed)",Several compound het cases reported,,47,618412,,"As of 2019, only 7 cases",GLS,GLS,NBK535148
chr7,27199678,27199732,27239297,27239351,27335815,27335849,(GCCGCGGCCGCCGCCG)1.9,HFG_HOXA13-III,HFG-III,-,NGC,NGC,,,,,,Hand-foot-genital syndrome 3,HOXA13,"""(NGC)*""",AD,Coding,Exon 1,8-18,8,18,,,,24-32,24,32,18.0,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK1423",There are 3 pathogenic polyalanine tracts in this gene,,54,140000,,Rare,HOXA13_3,HOXA13_3,NBK1423
chr7,27199825,27199861,27239444,27239480,27335914,27335954,(GCAGCCGCCGCCGCT)2.9,HFG_HOXA13-II,HFG-II,-,NGC,NGC,,,,,,Hand-foot-genital syndrome 2,HOXA13,"""(NGC)*""",AD,Coding,Exon 1,12,12,12,,,,18,18,18,12.0,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2,  NBK1423",There are 3 pathogenic polyalanine tracts in this gene,,36,140000,,Rare,HOXA13_2,HOXA13_2,NBK1423
chr7,27199924,27199966,27239543,27239585,27335920,27335951,(GCAGCCGCCGCCGCT)2.7,HFG_HOXA13-I,HFG-I,-,NGC,NGC,,,,,,Hand-foot-genital syndrome 1,HOXA13,"""(NGC)*""",AD,Coding,Exon 1,14,14,14,,,,22,22,22,14.0,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats, Gnomad v3.1.2, NBK1423",There are 3 pathogenic polyalanine tracts in this gene,,42,140000,,Rare,HOXA13_1,HOXA13_1,NBK1423
chr2,176093058,176093103,176957786,17695783,176581179,176581220,(GGC)14.0,SD5_HOXD13,SD5,+,GCG,GCG,,,,,,Syndactyly,HOXD13,"""(GCN)*""",AD,Coding,Exon 1,< 15,14,15,,,,>22,22,22,14.0,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,45,186000,,Unknown,HOXD13,HOXD13,NBK535148
chr4,3074877,3074940,3076604,3076667,3073604,3073694,(CAG)30.3,HD_HTT,HD,+,CAG,CAG,,,,,,Huntington disease,HTT,"""(CAG)*CAACAG(CCG)*""",AD,Coding,Exon 1,6–26,6,26,"27-35 unstable, 36-39 reduced penetrance",27,39,40–250 (>60 assocated with onset age <20),40,250,21.3,3,35-44,10,70,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews","CAG exp only pathogenic. Interruptions impact pathogenicity. Age 4 onset reported, not yet published",,63,143100,,"1/10,000",HTT,HTT,NBK1305
chr16,87604283,87604329,87637889,87637935,93675724,93675776,(GCT)17.3,HDL2_JPH3,HDL2,+,GCT,CTG,,,,,,Huntington disease-like 2,JPH3,"""(CTG)*""",AD,Coding,Exon 2,6–28,6,28,29-39,29,39,40–58,40,58,15.6667,3,12-66,12,66,ref,,"""unstable vertical transmission""",(doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK1529",reflen + pos from HipSTR,,46,606438,,"<1/1,000,000",JPH3,JPH3,NBK1529
chr8,104588972,104588999,105601200,105601227,105716410,105716441,(CGC)10.7,OPDM1_LRP12,OPDM1,-,CGC,CGC,,,,,,Oculopharyngodistal myopathy type 1,LRP12,"""(NCG)*""",AD,5' UTR,,13-45,13,45,,,,90,90,90,11.7,3,"Adult onset, variable (mean 22.1 in one study)",7,50,ref,RNA toxicity,RNA mediated toxicity hypothesized; unknown,"(OMIM), (doi.org/10.1007/s11604-022-01343-5)","OMIM 164310, Ishiura et al [2019], Ehdn, NBK535148, PMID 31332380",CGG/CGT,,27,164310,,Population dependent,LRP12,LRP12,NBK535148
chr5,10356339,10356411,10356451,10356523,10295521,10295593,(TTTTA)14.8,FAME3_MARCH6,FAME3,+,TTTTA,ATTTC,,,,"ATGTT,TAGTT,TTTTG,TTTTT",,Familial adult myoclonic epilepsy type 3,MARCH6,,AD,Intronic,Intron 1,0,,,,,,"791-1,035 repeats",791,1035,14.8,5,10-40,10,40,novel,Unknown,Noted as unknown in literature,(OMIM),"Florian, R.T. Nat Comm. 2019",TTTTA + TTTCA,,72,613608,,"~<1/35,000",MARCHF6,MARCHF6,NBK535148
chr15,22786677,22786701,23086366,23086390,20458505,20458536,(GCG)10.7,ALS1_NIPA1,ALS1,+,GCG,GCG,,,,,,Amyotrophic lateral sclerosis,NIPA1,"""(CGC)*""",AD,Coding,,6-10,6,10,,,,> 11,11,56,10.7,3,"Variable, 19-46 familial",19,46,ref,,No information found,N/A in GeneCard,"Pathogenic Short Tandem Repeats Gnomad v3.1.2, 30342764 (Pubmed), path range from gnomAD",Proposed modifier for ALS,,24,105400,"1.5-4.7 per 100,000 person-years (All ALS, Europe/NA)","2.7-7.4/100,000 (All ALS, not just this locus)",NIPA1,NIPA1,
chr20,2652733,2652775,2633379,2633421,2683200,2683242,(GCCTGG)8.8,SCA36_NOP56,SCA36,+,GGCCTG,GGCCTG,,,,,,Spinocerebellar ataxia type 36,NOP56,"""(GGCCTG)*(CGCCTG)*""",AD,Intronic,Intron 1,3 to 14,3,14,15-649,15,649,650-2500,650,2500,7.2,6,~52 (mean),48,57,ref,Protein toxic GOF,toxic gain-of-function mechanism,(OMIM),"GeneReviews, OMIM, NBK231880",,,42,614153,,Unknown,NOP56,NOP56,
chr1,149390803,149390842,,,148519696,148519738,(GGC)14.3,NIID_NOTCH2NLC,NIID,+,CGG,GGC,,,,,,"Neuronal intranuclear inclusion disease, Alzheimer disease and parkinsonism phenotype",NOTCH2NLC,,AD,5' UTR,5' Region,7–39,7,39,,,,66-517,66,517,13.3,3,16-76,16,76,ref,Unknown,May relate to methylation or RNA pathogenicity; Unknown,(OMIM) (doi.org/10.1007/s11604-022-01343-5),"doi: 10.1038/s41588-019-0458-z, https://doi.org/10.1016/j.ajhg.2019.05.013, s40478-021-01201-x","May be issues with parology between genes: C253572.1, NOTCH2, NOTCH2NL, NBPF14, NBPF19 ?? Motif variation in controls: (AGG)(CGG)n(AGG)0-3(CGG)0-2. Methylation involved",,39,603472,,Unknown,NOTCH2NLC,NOTCH2NLC,NBK535148
chr10,79826383,79826404,81586139,81586160,80695712,80695748,(GCG)12.7,OPML1_NUTM2B-AS1,OPML1,+,GGC,GGC,,,,,,Oculopharyngeal myopathy with leukoencephalopathy 1,NUTM2B-AS1,,AD,lncRNA,Exon 1 (noncoding),3-16,3,16,,,,>700,700,700,7.0,3,,15,40,ref,RNA toxicity,"RNA mediated toxicity hypothesized, unknown",(OMIM) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, Ishiura 2019, doi: 10.1038/s41588-019-0458-z, https://doi.org/10.1038/s41580-021-00382-6","Not in TRF annotation, alt transcript in opposite direction: LOC642361",,21,618637,,Couldn't find,NUTM2B-AS1,NUTM2B-AS1,NBK535148
chr14,23321472,23321492,23790681,23790701,17522488,17522508,,OPMD_PABPN1,OPMD,+,CGG,GCG,,,,,,Oculopharyngeal muscular dystrophy,PABPN1,"""(GCN)*""",AD/AR,Coding,Exon 1,10,10,10,,,,12-17,12,17,7.0,3,26-65,26,65,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, GeneReviews NBK1126, s40478-021-01201-x","AR for 11 repeats, AD >12 repeats. Most known patients have (GCG)+, but GCN or any polyalanine may be pathogenic",,20,164300,,"1/100,000 Western countries",PABPN1,PABPN1,NBK1126
chr4,41745976,41746022,41747993,41748039,41719749,41719795,(GCC)15.7,CCHS_PHOX2B,CCHS,-,GCC,GCN,,,,,,Congenital central hypoventilation syndrome,PHOX2B,"""(GCN)*""",AD,Coding,Exon 3,20,15,20,24,24,24,25-33,25,33,15.7,3,0-20,0,20,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Mirkin 2007, GeneReviews NBK1427, s40478-021-01201-x",ReferenceRegion: 4:41745971-41746032,,46,209880,,1:148000-200000 births (Estimated),PHOX2B,PHOX2B,NBK1427
chr15,89333589,89333629,89876820,89876860,87088412,87088452,(GCT)13.7,CPEO_POLG,CPEO,-,GCT,GCT,,,,,,"Progressive external ophthalmoplegia, Parkinson’s disease",POLG,"""(CTG)*TTG(CTG)*""",,,,"10-12, < 15",10,15,,,,> 10000,10000,10000,13.7,3,23-87,23,87,ref,,No information found,N/A in GeneCard,"PMC2905783, PMID: 20399836, PMID: 10196696",Unconfirmed association,There is conflicting evidence for the association between this repeat expansion and Parkinson's risk (PMID: 20399836 and PMID: 10196696),40,Disease association unclear,,,,,
chr5,146878728,146878759,146258291,146258322,147414734,147414765,(GCT)15.7,SCA12_PPP2R2B,SCA12,-,CAG,GCT,,,,,,Spinocerebellar ataxia type 12,PPP2R2B,"""(GCT)*""",AD,Promoter,,4–32,4,32,,,,51–78,51,78,10.7,3,8-55,8,55,ref,Unknown,Noted as unknown in literature,"N/A in GeneCard,","Hannan 2018, Mirkin 2007, OMIM, NBK535148, s40478-021-01201-x",(Roda et al. suggested that the ATXN8 or ATXN8OS gene should not be evaluated in isolation as a candidate gene for spinocerebellar degenerative disease),,31,604326,,Unknown,PPP2R2B,PPP2R2B,NBK535148
chr9,130681606,130681639,133556993,133557026,142886569,142886595,(CGC)9.0,HSAN-VIII_PRDM12,HSAN VIII,+,GCC,GCC,,,,,,Hereditary sensory and autonomic neuropathy type VIII,PRDM12,"""(GCC)*""",AR,Coding,Exon,<14,12,14,,,,>18,18,18,12.0,3,0,0,0,ref,"LOF, epigenetic","""mutations abrogated the histone-modifying potential of PRDM12, consistent with a loss of function""",OMIM,Pathogenic Short Tandem Repeats Gnomad v3.1.2,,,33,616488,,"<1/1,000,000",PRDM12,PRDM12,NBK535148
chr4,159342527,159342618,160263679,160263770,162693304,162693405,(TTTTA)20.4,FAME7_ RAPGEF2,FAME7,+,TTTTA,ATTTC,,,,"TTTTT,TTATG",,Familial adult myoclonic epilepsy type 7,RAPGEF2,"""(TTTTA)*(TTTCA)*(TTTTA)*""",AD,Intronic,Intron 14,0-1,0,1,,,,>=60,60,60,17.4,5,"~18, 23-37",18,37,novel,RNA toxicity,RNA toxicity hypothesized,(10.1038/s41588-018-0067-2),"Ishiura 2018, 29507423 (Pubmed), https://sci-hub.hkvisa.net/10.1111/ene.13848","Novel, (TTTTA)exp(TTTCA)exp(TTTTA)n, but only the TTTCA is specific to affected individuals, Alu-associated repeat, incomplete penetrance",,91,618075,,"~<1/35,000",RAPGEF2,RAPGEF2,NBK535148
chr4,39348425,39348483,39350045,39350103,39318078,39318136,(AAAAG)11.8,CANVAS_RFC1,CANVAS,-,AAAAG,"AAGGG, ACAGG",,"AAAAG,AAAGG, AAGAG, AGAGG",,"AAAAA,AAAAC,AACGG,AAGAC,AAGGC,AAGGT,AGAAC,AGGGC,AGGGG,GAAAC,GGGAC,GTGAG,AAAAGA,AAAGGA,GGAAAG",,"Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome",RFC1,"""(AARRG)*""",AR,Intronic,Intron 2,0-11,0,11,,,,>400,400,2000,11.8,5,33-71,33,71,novel,,No information found,N/A in GeneCard,"OMIM, Cortese 2019, 30926972 (Pubmed), https://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01201-x/tables/1, s40478-021-01201-x, https://www.ncbi.nlm.nih.gov/books/NBK564656/, https://doi.org/10.1101/2023.05.12.540470","Novel, ref is AAAAG(11), path: (AAGGG)400–2000 or (ACAGG)exp","Pathogenic expansions may be flanked by other motifs. For example, (AAAGG)10-25(AAGGG)exp(AAAGG)4-6 (PMID: 32851396). Motif heterogeneity is common in unaffected individuals",58,614575,,"Unknown, <1/1,000,000",RFC1,RFC1,NBK564656
chr12,123533720,123533755,124018267,124018302,123532574,123532608,(GGC)11.7,OPDM4_RILPL1,OPDM4,-,CGG,GGC,,,,,,Oculopharyngodistal myopathy type 4,RILPL1,,AD,5' UTR,,9-16,9,16,,,,139 to 197,139,197,11.7,3,,14,27,ref,Protein toxic GOF,"toxic gain-of-function mechanism ",(Malacard),Yu 2022 AJHG,toxic poly-glycine protein and/or toxic RNA gain-of-function effects,,35,,,Population dependent,RILPL1,,
chr6,45422750,45422792,45390487,45390529,45257567,45257611,(GGC)15.0,CCD_RUNX2,CCD,+,GCN,GCN,,,,,,Cleidocranial dysplasia,RUNX2,"""(GCN)*""",AD,Coding,Exon 3,<17,4,17,,,,>27,27,27,15.0,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,42,119600,,"1/1,000,000 births (likely underdiagnosed)",RUNX2,RUNX2,NBK1513
chr8,118366813,118366918,119379052,119379157,119495248,119495353,(AAATA)21.6,FAME1_SAMD12,FAME1,-,AAATA,"ATTTC,TTTGA",,,,"AAAAA,TAAAC,TAACA,TACAA,TACAC",,Familial adult myoclonic epilepsy type 1,SAMD12,"""(TAAAA)*(TGAAA)*(TAAAA)*""",AD,Intronic,Intron 4/4,0,0,0,,,,105–3680,105,3680,21.6,5,18-50,18,50,novel,RNA toxicity proposed,RNA molecules,(OMIM),Ishiura 2018. https://movementdisorders.onlinelibrary.wiley.com/doi/full/10.1002/mds.27832,"Novel, pathogenic alleles include expansions of TTTTAn + TTTCAn, but only the TTTCA is specific to affected individuals, check reference and pathogenic sites with Stranger. TTTCA within TTTTA repeat region",,105,601068,,"~<1/35,000",SAMD12,SAMD12,NBK535148
chrX,140504316,140504361,139586481,139586526,138816205,138816239,(GCGGCAGCGGCGGCGG)1.9,XLMR_SOX3,XLMR,-,NGC,NGC,,,,,,"X-linked panhypopituitarism ; X-linked mental retardation with isolated growth hormone    ",SOX3,"""(NGC)*""",XR,Coding,Exon 1,< 15,15,15,,,,> 22,22,26,15.0,3,Infancy - childhood,0,9,ref,Polyalanine,Polyalanine,(doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,45,300123,,,SOX3,SOX3,NBK535148
chr2,96197067,96197121,96862805,96862859,96703675,96703729,(AAAAT)11.6,FAME2_STARD7,FAME2,-,AAAAT,ATTTC,,,,"AAAAA,AAAAC,AAACC,AAACG,AAACT,AACTC,AACTG,AATAC,AATAG,ATAAC",,Familial adult myoclonic epilepsy 2,STARD7,,AD,Intronic,,0,0,0,,,,>274,274,274,11.6,5,mean 25,5,60,novel,RNA toxicity,"RNA toxicity ",(10.1038/s41467-019-12671-y),Pathogenic Short Tandem Repeats Gnomad v3.1.2,,,54,607876,,"~<1/35,000",STARD7,STARD7,NBK535148
chr6,170561907,170562017,170870995,170871105,171935459,171935569,(GCA)37.0,SCA17_TBP,SCA17,+,CAG,GCA,,,,,,Spinocerebellar ataxia type 17,TBP,"""(GCA)*""",AD,Coding,Exon 3,25–40,25,40,41–48,41,48,49 to 66,49,66,37.0,3,Most >30,3,55,ref,"Polyglutamine ","Polyglutamine ",(doi.org/10.1038/nrg.2017.115) (doi.org/10.1007/s11604-022-01343-5),"Hannan 2018, Mirkin 2007, GeneReviews NBK1438","Parkinson disease,late-onset",,110,607136,,"Unknown (global), 0.47:1,000,000 (Japanese)",TBP,TBP,NBK1438
chr22,19766762,19766807,19754285,19754330,20143615,20143660,,OTF_TBX1,OTF,+,GCN,GCN,,,,,,Tetralogy of Fallot,TBX1,"""(GCN)*""",AD,Coding,,<15,15,15,,,,>25,25,25,15.0,3,0,0,0,ref,Polyalanine,Polyalanine,(OMIM),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,45,187500,,Unknown for specific gene,TBX1,TBX1,NBK535148
chr18,55586155,55586227,53253386,53253458,55789234,55789288,(AGC)18.3,FECD3_TCF4,FECD3,-,CAG,CAG,,,,,,Fuchs endothelial corneal dystrophy 3,TCF4,"""(CAG)*""",AD,Intronic,Intron 1,10 - 40,10,40,,,,>50,50,150,25.3,3,~40,32,70,ref,RNA toxicity proposed,"""sequestration of MBNL1 in RNA foci, similar to the mechanism underlying myotonic dystrophy-1 """,(10.1074/jbc.M114.621607),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,72,613267,,~4/100 (over 40),TCF4,TCF4,NBK535148
chr16,24613439,24613532,24624760,24624853,24890367,24890430,(ATTTT)12.8,FAME6_ TNRC6A,FAME6,+,ATTTT,ATTTC,,,,TTTTT,,Familial adult myoclonic epilepsy type 6,TNRC6A," ""(TTTTA)*(TTTCA)*(TTTTA)*""",AD,Intronic,,0,0,0,,,,">1100, >=10, 29",1100,1100,18.8,3,20s-70s,20,70,novel,RNA toxicity,RNA toxicity hypothesized,(10.1038/s41588-018-0067-2),"Ishiura 2018; gnomad v3.1.2, 29507423 (Pubmed), https://doi.org/10.1038/s41597-020-00633-9, https://stripy.org/database/TNRC6A","Novel, reported pathogenic alleles: (TTTTA)22 (TTTCA)exp (TTTTA)exp, but only the TTTCA is specific to affected individuals, Alu-associated repeat. Non-pathogenic reference TTTTA repeat was expanded in nine healthy subjects 40-120 repeats and in two individuals potentially even longer (Ishiura et al., 2018).",,93,618074,,"~<1/35,000",TNRC6A,TNRC6A,NBK535148
chr16,17470921,17470922,17564778,17564779,17477910,17478013,(GCC)34.7,DBQD2_XYLT1,"DBQD2, BSS",-,CCG,GCC,,,,,,Baratela-Scott Syndrome/Desbuquois dysplasia 2,XYLT1,"""(GGC)*""",AR,Promoter,Intron 1,<20,0,20,,,,>72,72,110,0.0,3,0,0,0,ref,Methylation,Methylation,(doi.org/10.1016/j.ajhg.2018.11.005),"LaCroix 2019, gnomad v3.1.2, 30554721",Repeat is within a sequencing missing from hg38,,1,615777,,"<1 / 1,000,000 births",XYLT1,XYLT1,NBK535148
chr3,183712188,183712222,183429976,183430010,186521657,186521706,(ATTTT)10.0,FAME4_YEATS2,FAME4,+,TTTTA,ATTTC,,,,"TTTTT,TGTTA",,Familial adult myoclonic epilepsy 4,YEATS2,,AD,Intronic,,0,0,0,,,,>1000,1000,1000,10.0,5,19.5 years (range 10-33) for tremor and 25 years (range 19-33) for seizures,10,33,novel,RNA toxicity,RNA toxicity hypothesized,(10.1093/brain/awz267),Pathogenic Short Tandem Repeats Gnomad v3.1.2,,,34,615127,,"~<1/35,000",YEATS2,YEATS2,NBK535148
chr13,99985448,99985493,100637702,100637747,99196359,99196404,(GCG)15.3,HPE5_ZIC2,HPE5,+,GCN,GCN,,,,,,Holoprosencephaly-5,ZIC2,"""(GCN)*""",AD,Coding,Exon 3,< 15,15,15,,,,>25,25,25,15.3,3,0,0,0,ref,"Polyalanine ","Polyalanine ",(doi.org/10.1038/nature05977) (doi.org/10.1007/s11604-022-01343-5),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,45,609637,,Unknown ZIC2 specific,ZIC2,ZIC2,NBK535148
chrX,137566826,137566856,136648985,136649015,135876774,135876800,(CGC)9.0,VACTERLX_ZIC3,VACTERLX,+,GCN,GCN,,,,,,X-linked VACTERL syndrome,ZIC3,"""(GCN)*""",XR,Coding,,<10,9,10,11,11,11,>12,12,12,9.0,3,0,0,0,ref,Polyalanine,Polyalanine,(doi.org/10.1038/nature05977),"Pathogenic Short Tandem Repeats Gnomad v3.1.2, NBK535148",,,30,314390,,Unknown,ZIC3,ZIC3,NBK535148
chr7,55887601,55887639,55955294,55955332,56047901,56047939,(GCG)15.0,FRA7A_ZNF713,FRA7A,+,GCG,CGG,,,,,,Autism spectrum disorder associated with fragile site FRA7A,ZNF713,,AD,Intronic,,5-22,5,22,85,85,85,450,450,450,13.0,3,,,,ref,Methylation,Methylation,(OMIM),"OMIM, https://pubmed.ncbi.nlm.nih.gov/25196122/",,,38,616181,,,,,
chr3,129172577,129172659,128891420,128891502,131917483,131917557,(CAGG)18.8,DM2_CNBP1,DM2,-,CAGG,CAGG,,,,,,Myotonic Dystrophy Type 2,ZNF9 / CNBP1,"""(CAGG)*(CAGA)*(CA)*""",AD,Intronic,,11–26,11,26,27-74,27,74,"75-11,000",75,11000,20.8,4,~30-40,30,40,ref,Aberrant splicing,Aberrant splicing,(doi.org/10.1093/hmg/ddr568),"Hannan 2018, Mirkin 2007, GeneReviews NBK1466, https://doi.org/10.1038/s41580-021-00382-6",(TG)n(TCTG)n(CCTG)n. CCTG expansion causes DM2 but the other repeat units are also variable.,,82,602668,,"2.29/100,000",CNBP,CNBP,NBK1466
chr21,43776443,43776479,,,42132055,42132091,,EPM1_CSTB,EPM1,-,CGCGGGGCGGGG,CGCGGGGCGGGG,,,,,,Progressive Myoclonic Epilepsy Type 1 (EPM1) Unverricht-Lundborg Disease (ULD),CSTB,"""(CGCGGGGCGGGG)*""",AR,Promoter,,2-3,2,3,12-17,12,17,>=30,30,,,12,6-15,6,15,,,,,"OMIM, https://www.ncbi.nlm.nih.gov/books/NBK1142/, PMID: 9126745",,,,254800,,,,CSTB,NBK1142
chr17,80147059,80147139,,,81047454,81047534,,RCPS_EIF4A3,RCPS,-,CCTCGCTGTGCCGCTGCCGA,CCTCGCTGTGCCGCTGCCGA,,,,,,Richieri-Costa-Pereira syndrome,EIF4A3,"""(CCTCGCTGCGCCGCTGCCGA)*(CCTCGCTGTGCCGCTGCCGA)*""",AR,5'UTR,,1-9,1,9,10-13,10,13,>14,14,,,,0,0,,,,,,https://www.ncbi.nlm.nih.gov/books/NBK535148/,,,,268305,,,,EIF4A3,NBK535148
chr20,4699397,4699493,,,4738633,4738705,,CJD_PRNP,CJD,+,,CCTCATGGTGGTGGCTGGGGGCAG,,,,,,Creutzfeldt-Jakob disease,PRNP,,AD,Coding,Exon 2,<=4,,4,,,,>=5,5,,,,middle age,,,,,,,https://www.ncbi.nlm.nih.gov/books/NBK1229/,,,,123400,,,,PRNP,NBK1229
chr1,1435798,1435818,,,870158,870178,,HMNR7_VWA1,HMNR7,+,,GGCGCGGAGC,,,,,,"Neuronopathy, distal hereditary motor, autosomal recessive 7",VWA1,,AR,Coding,Exon 1,2,2,2,,,,>=3,3,,,,<10,,10,,,,,,,,,619216,,,,VWA1,NBK535148
chr1,94418422,94418444,,,94266545,94266567,,OPDM_ABCD3,OPDM,+,GCC,GCC,,,,,,Oculopharyngodistal myopathy,ABCD3,"""(GCC)*""",AD,5'UTR,,3-44,3,44,,,,118-694,118,694,7.7,3,average age of onset was 26.7 years (range: 10-50 years),10,50,,,,,https://doi.org/10.1101/2023.10.09.23296582,,,,,,,,,
chr13,102161577,102161726,,,101377640,101377789,,SCA27B_FGF14,SCA27B,-,AAG,AAG,,,,,,Spinocerebellar ataxia 27B,FGF14,,AD,Intronic,Intron 1,,,,,,,,250,450,50.3,,,,,,,,,"https://www.omim.org/entry/620174, https://www.cell.com/ajhg/fulltext/S0002-9297(22)00506-7","250-300 pathogenic with incomplete penetrance, >300 complete penetrance",,,620174,,,FGF14,,